Breast cancer is the most common cancer in women worldwide. Treatment depends on cancer type, stage, and molecular markers like HER2, hormone receptors, and BRCA mutations. Many early-stage breast cancers are now curable, and even metastatic disease often responds to treatment for years.
What's actually going on in research
Trials are testing antibody-drug conjugates that deliver chemotherapy directly to cancer cells, immunotherapy combinations for triple-negative disease, CDK4/6 inhibitors in earlier stages, PARP inhibitors for BRCA-mutated cancers, and less intensive regimens to reduce treatment burden while maintaining outcomes. Researchers are also studying ways to predict which patients can skip chemotherapy or radiation.
Antibody-drug conjugates
These drugs combine a targeted antibody with chemotherapy, delivering the treatment directly to cancer cells. Trastuzumab deruxtecan and sacituzumab govitecan have already changed practice, and newer versions are being tested across more breast cancer types.
De-escalation trials
Studies are testing whether some patients can safely receive less surgery, chemotherapy, or radiation. The goal is to maintain cure rates while reducing side effects and long-term complications.
Immunotherapy expansion
Checkpoint inhibitors like pembrolizumab now have FDA approval for some triple-negative breast cancers. Trials are testing whether immunotherapy works in hormone-positive disease and whether combining it with other treatments improves outcomes.
What to know before you search
Eligibility typically depends on cancer stage, receptor status (ER, PR, HER2), BRCA or other genetic mutations, prior treatments, and overall health.
What types of trials are currently open
- Treatment trials — Testing new drugs or combinations, often comparing them to standard chemotherapy, targeted therapy, or hormone therapy.
- Surgery trials — Studies of whether less extensive surgery can be as effective as more aggressive approaches, especially in early-stage disease.
- Prevention trials — Testing medications or lifestyle interventions in people at high risk for developing breast cancer.
- Biomarker trials — Using genetic tests or imaging to match patients to treatments or to decide who can skip certain therapies.
- Supportive care trials — Testing treatments for side effects like neuropathy, cognitive changes, or bone loss caused by cancer or its treatment.
Recently added Breast Cancer trials
Try an AI-powered app to manage symptoms during breast cancer treatment
This randomized controlled clinical trial aims to evaluate the effects of an artificial intelligence-supported mobile application on symptom management, self-efficacy, and quality of life in breast cancer patients receiving chemotherapy. The study will be conducted between June 2026 and December 2026 at the Ege University Hospital Berna Türek Chemotherapy Center and the İzmir City Hospital Chemotherapy Center. Seventy breast cancer patients who will receive chemotherapy for the first time will be randomly assigned to either an intervention group using the mobile application or a control group receiving standard care. The study seeks to answer the following key questions: Does the artificial intelligence-supported mobile application improve symptom management? Does use of the application increase patients' self-efficacy? Does the application improve quality of life compared with standard care? Participants in the intervention group will use the mobile application during chemotherapy, report daily symptoms, and receive personalized symptom-management recommendations generated by an artificial intelligence system trained by the research team. Participants in both groups will complete symptom, self-efficacy, and quality-of-life assessments at baseline, after the first chemotherapy cycle (cycle length varies by chemotherapy protocol; all cycles are defined according to each patient's prescribed treatment regimen), and after the fourth cycle. The control group will receive standard care and complete the same assessments through face-to-face visits. This study is designed to assess the effectiveness of artificial intelligence-supported mobile health interventions in breast cancer care and their potential to improve symptom management, self-efficacy, and quality of life.
Try a supervised exercise program during breast cancer chemotherapy
Breast cancer is the most prevalent malignancy among women in Brazil, and Porto Alegre (Rio Grande do Sul) has one of the highest incidence rates in women under 50, with 165.5 cases per 100,000 women aged 40-49. Advances in cancer biology, treatment, and supportive care have improved outcomes, leading to increased survivorship. Regular physical exercise has been shown to be an effective strategy in both the prevention and management of breast cancer, and during chemotherapy, physical activity may reduce fatigue, improve quality of life, and increase cardiorespiratory fitness. This randomized clinical trial will enroll women diagnosed with breast cancer indicated for neoadjuvant or adjuvant chemotherapy. The study aims to characterize the clinical profile of these patients with respect to cardiovascular and functional effects of chemotherapy, and to evaluate an integrated cardio-oncology rehabilitation approach. The investigators expect to identify the clinical profile of breast cancer patients undergoing chemotherapy and establish associations with the study variables, as well as to assess the effect of a standardized exercise program on the cardiovascular and musculoskeletal systems and quality of life. Based on these results, the study aims to propose a complementary rehabilitation program, to be offered within the public health system, alongside pharmacological treatment during and after completion of the chemotherapy cycle.
Find Breast Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.